Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | High economic burden for progressive multiple myeloma: considering costs

The progression of multiple myeloma has been found to pose a significant economic burden. Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, and urges the medical community to consider the long-term, with more expensive treatments potentially giving greater disease control and durable remission further downstream.